


# tenacio Wins 2024 Digital Health Pitch Competition Award at 2024 DTA Summit



Berlin/Washington, 11 June 2024

FOR IMMEDIATE RELEASE

tenacio is proud to announce that its CEO, Georg van Husen, has been awarded the prestigious 2024 Digital Health Pitch Competition Award at the 2024 DTA Summit in Washington, DC. The annual event, organized by the Digital Therapeutics Alliance (DTA), brought together innovators and thought leaders in the digital health industry to share and discuss the latest advancements and cutting-edge solutions.

The Digital Health Pitch Competition Award, voted on by a panel of esteemed judges, recognizes tenacio for its groundbreaking contributions to the digital therapeutics space. Georg van Husen's compelling pitch presentation captivated the judges, highlighting tenacio's commitment to revolutionizing healthcare through innovative digital solutions.

"We are honored to receive this award and grateful for the recognition from the esteemed panel of judges at the 2024 DTA Summit," said Georg van Husen, CEO of tenac.io GmbH. "This achievement is a testament to the hard work and dedication of our team in advancing digital therapeutics and improving patient outcomes."

Andy Molnar, CEO of the Digital Therapeutics Alliance, commented, "The level of innovation and dedication showcased by tenac.io GmbH is truly inspiring. Georg van Husen and his team are at the forefront of digital health advancements, and their work is poised to make a significant impact on patient care. We are thrilled to present them with this well-deserved award."

The 2024 DTA Summit provided a platform for finalists to showcase their innovative solutions, fostering collaboration and knowledge exchange within the digital therapeutics community. The event showcased the industry's commitment to driving positive change and improving patient care through technology.

tenac.io GmbH extends its heartfelt thanks to the DTA, the 2024 DTA Summit attendees, and the panel of judges for this esteemed recognition.

## **About tenacio**

tenacio is a pioneering healthcare technology company focused on revolutionizing cardiovascular care through innovation and evidence-based solutions. Our flagship product, OptiCor<sup>®</sup>, is a cutting-edge Clinical Decision Support Software designed to optimize treatment decisions for atrial fibrillation (AF) and other cardiovascular diseases. With a validated risk prediction algorithm and seamless integration with clinical guidelines, OptiCor<sup>®</sup> empowers healthcare professionals to make informed, personalized decisions, leading to improved patient outcomes. Backed by a team of experienced physicians, strategic collaborations with leading institutions, and a commitment to excellence, tenacio is poised to lead the transformation of cardiovascular care and deliver significant value to patients, providers, and investors alike.

## **About Digital Therapeutics Alliance (DTA)**

As the leading global authority on the evolution of digital health technology, Digital Therapeutics Alliance (DTA) is a 501(c)(6) non-profit trade association of industry leaders and stakeholders dedicated to the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. As the leading international organization on digital therapeutic thought leadership and education, DTA provides the digital health ecosystem with the necessary tools to define, evaluate, and utilize DTx products.

### **MEDIA CONTACT:**

Dr. Georg van Husen, Co-founder & CEO

tenac.io, Inc

447 Broadway, 2/F #45

New York, NY 10013

+1 212 252-2168

[georg.van\\_husen@tenac.io](mailto:georg.van_husen@tenac.io)

[www.tenac.io](http://www.tenac.io)